Disaggregation and reaggregation of 'irreversibly' aggregated platelets: a method for more complete evaluation of anti-platelet drugs.

摘要: Anti-platelet drugs are generally screened by evaluating their ability to influence initiation and development of irreversible aggregation platelets. However, fully characterize the inhibitory effects an agent, it is essential determine if can also disperse irreversibly aggregated cells, whether drug-treated, dispersed platelets refractory, sensitive some but not all aggregating agents, as agents before initial exposure, hypersensitive or they be restored a state modulation platelet membrane. We have developed anvitro system for variety on disaggregation reaggregation blood Results demonstrate that which inhibit cause disaggregation, while others cannot. The disaggregate often selective, revealing dependence nature agent causing aggregation, time after inhibitor added. Agents elevate intracellular cyclic adenosine monophosphate levels were potent inducers dissociation in aggregates caused diphosphate. On other hand, antimalarials, calmodulin complexing phospholipase inhibitors aggregates, irrespective agonist used. By large, dissociated cells refractory action agonists. Restoration sensitivity disaggregated treatment with epinephrine treated, recover full functional capacity almost immediately. Thus, careful study recovery may reveal features critical selection anti-platelet clinical utilization.